Evaluation of the Potentiating Effect of tDCS on Opioid Analgesia of Pain Threshold in Humans
Evaluation of the Potentiating Effect of Transcranial Direct Current Stimulation (tDCS) on Opioid Analgesia of Pain Threshold in Humans
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Gilberto Braulio, MD
- Phone Number: +555183008300
- Email: gbraulio@hcpa.ufrgs.br
Study Contact Backup
- Name: Wolnei Caumo, MD, P.h.D
- Phone Number: +55 51 99813977
- Email: caumo@cpovo.net
Study Locations
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035-003
- Recruiting
- Hospital de Clinicas e Porto Alegre (HCPA)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male
- Healthy
- Without medication
- Sign the informed consent
Exclusion Criteria:
- Patients who did not understand the Portuguese
- Acute or chronic pain conditions
- Medical or psychiatric disorders
- History of sleep disorders (apnea, hypersomnia, somnambulism…)
- History of alcohol or substance abuse
- Neurological disorder
- Use of anti-inflammatory drugs, steroids and non-steroids, opioid and non-opioid analgesics, psychiatric medications, anticonvulsants, alpha and beta blockers
- Traumatic brain injury
- Neurosurgery
- Metallic implant in the brain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Remifentanil + Active tDCS
|
Remifentanil (IV infusion): 0,06mcg.kg.min.
The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline.
A battery-powered constant current stimulator will be used for this purpose (tDCS device).
The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
Other Names:
|
|
Other: Placebo + Active tDCS
|
The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline.
A battery-powered constant current stimulator will be used for this purpose (tDCS device).
The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
Other Names:
Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
|
|
Other: Remifentanil + Sham tDCS
|
Remifentanil (IV infusion): 0,06mcg.kg.min.
The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it).
The rest of the montage is kept identical to the active one during the 20 minutes session.
Other Names:
|
|
Other: Placebo + Sham tDCS
|
Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it).
The rest of the montage is kept identical to the active one during the 20 minutes session.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Thresholds of pain to the cold pressor test (CPT)
Time Frame: 20min
|
20min
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum levels of BDNF
Time Frame: 20min
|
20min
|
|
|
Intensity of electrical brain activity in the bi-spectral index (BIS)
Time Frame: 60min
|
60min
|
|
|
Sedation level in the visual analogue scale (VAS)
Time Frame: 60min
|
60min
|
|
|
Temperature of tolerance to the thermal stimulus (TTTS)
Time Frame: 20min
|
20min
|
|
|
Conditioned pain modulation (CPM)
Time Frame: 20min
|
A nociceptive tonic conditioning stimulus - immersion of the non-dominant hand in cold water (0°C for 1 minute) - will be applied concomitant to the progressive thermal stimulus in the dominant forearm as applied in the QST pattern until it reaches the 6/10 pain temperature previously determined by the participant.
|
20min
|
|
Threshold of pain to the thermal stimulus (TT)
Time Frame: 20min
|
20min
|
|
|
Hemodynamic changes of brain using fNIRSNear-infrared spectroscopy (NIRS)
Time Frame: 60
|
The vascular response will be assessed using functional near infrared spectroscopy (fNIRS).
Emerging technique that allows the functional mapping of the brain, with a better understanding of the neuro-vascular coupling, the neurophysiological fluctuations and cerebral hemodynamics.
|
60
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wolnei Caumo, MD, P.h.D, Hospital de Clinicas de Porto Alegre - UFRGS
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14-0217
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.